Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00940342 · ClinicalTrials.gov registry record · Phase 2
Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
NCT00940342: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00940342 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 130 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00940342, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if giving granulocyte-macrophage colony-stimulating factor (GM-CSF) together with rituximab can improve the ability of rituximab to shrink or slow the growth of Chronic Lymphocytic Leukemia (CLL). The safety of this combination treatment will also be studied.
Interventions
- DRUG Rituximab
- DRUG GM-CSF (Sargramostim)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2004-10-12 |
| Est. Completion | 2017-01-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00940342
The ClinicalTrials.gov registry entry for NCT00940342 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT00940342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00940342 about?
NCT00940342 is a clinical study titled "Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia". The goal of this clinical research study is to learn if giving granulocyte-macrophage colony-stimulating factor (GM-CSF) together with rituximab can improve the ability of rituximab to shrink or slow the growth of Chronic Lymphocytic Leukemia (CLL). The safety of this combination treatment will also...
What is the current status of trial NCT00940342?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2004-10-12. Estimated completion is 2017-01-05.
What interventions are being tested in trial NCT00940342?
The interventions under investigation include: Rituximab (DRUG), GM-CSF (Sargramostim) (DRUG).
Who is sponsoring clinical trial NCT00940342?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.